Oorsprong van het eerstegraads netwerk van Mike Ross
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.
44
| Holding Company | Investment Managers | 44 |
Eyebiotech Ltd.
 Eyebiotech Ltd. BiotechnologyHealth Technology Eyebiotech Ltd. develops new generation of therapies for eye diseases. The British company was founded in 2021 by David R. Guyer, Anthony P. Adamis. David R. Guyer has been the CEO since 2021.
7
| Holding Company | Biotechnology | 7 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Mike Ross via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | Investment Trusts/Mutual Funds | Chief Investment Officer Director of Finance/CFO | |
Schroder Investment Management Ltd.
 Schroder Investment Management Ltd. Investment ManagersFinance Schroder Investment Management Ltd. (SIM) is the wholly-owned asset management subsidiary of Schroder International Holdings Ltd., ultimately held by Great Britain-based Schroders Plc (LSE: SDR, ADR: SHNWY). Established in 1985, SIM is headquartered in London and caters to a range of clients such as corporations, insurance firms, local and public authorities, charities, pension funds, high net-worth individuals and retail investors. | Investment Managers | Portfolio Manager-Equities Portfolio Manager-Equities | |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Biotechnology | Director/Board Member Director/Board Member Founder Chief Tech/Sci/R&D Officer | |
Vaxess Technologies, Inc.
 Vaxess Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Vaxess Technologies, Inc. provides global vaccine access distribution services. It develops a pipeline of next-generation MIMIX therapies. The firm provides MIMIX oncology and MIMIX infectious disease. The company was founded by Patrick Ho, David Kaplan, Kathryn Kosuda, Fiorenzo Omenetto, Michael Schrader and Livio Valenti in 2012 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree | |
| Stanford University | College/University | Doctorate Degree Graduate Degree | |
| University of Oxford | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Rice University | College/University | Undergraduate Degree Undergraduate Degree | |
Oxagen Ltd.
 Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| University of Cambridge | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
| EYEPOINT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
De Novo Ventures LLC
 De Novo Ventures LLC Investment ManagersFinance De Novo Ventures LLC (De Novo ventures) is a venture capital firm founded in 2000 by Frederick Dotzler, Richard Ferrari and David Mauney. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Analyst | |
SV Health Investors LLC
 SV Health Investors LLC Investment ManagersFinance SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
| University of Richmond | College/University | Undergraduate Degree Undergraduate Degree | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Puretech Health LLC
 Puretech Health LLC Investment ManagersFinance Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Analyst Private Equity Investor | |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Director/Board Member | |
| IVERIC BIO, INC. | Pharmaceuticals: Generic | Director/Board Member Chief Executive Officer | |
SV Health Managers LLP
 SV Health Managers LLP Investment ManagersFinance SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest. | Investment Managers | Chief Executive Officer Analyst-Equity Analyst-Equity Portfolio Manager-Equities | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| Solspark, Inc. | Private Equity Investor | ||
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
| MASSMEDICA S.A. | Medical Distributors | Director/Board Member | |
Weatherden Ltd.
 Weatherden Ltd. BiotechnologyHealth Technology Weatherden Ltd. is a pioneering clinical development consulting group based in London, UK. The British company specializes in scientific strategy, translational medicine, clinical development, diligence preparation, and support for M & A. Weatherden focuses on de-risking programs early and optimizing clinical, regulatory, and commercial pathways to bring life-changing medicines to patients. With over 750 years of combined industry experience, they are dedicated to improving the chances for breakthrough therapies to address unmet clinical needs. The private company, founded by Duncan McHale and Houman Ashrafian, provides trusted advice to biopharma, funds, startups, spin-outs, and nonprofits. Emma Tinsley has been the CEO of the company since 2017. | Biotechnology | Founder Chief Executive Officer | |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member Founder Corporate Officer/Principal | |
Ervaxx Ltd.
 Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Affera, Inc.
 Affera, Inc. Medical SpecialtiesHealth Technology Affera, Inc. manufactures medical devices for cardiac arrhythmia treatment. The firm develops system to treat heart rhythm disorders. The company was founded by Doron Harlev and is headquartered in Watertown, MA. | Medical Specialties | Director/Board Member | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
Therini Bio, Inc.
 Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Tiaki Therapeutics, Inc.
 Tiaki Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tiaki Therapeutics, Inc. develops novel therapeutics for Alzheimer's disease. The company was founded by Barbara Tate and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Founder | |
Alchemab Therapeutics Ltd.
 Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Biotechnology | Director/Board Member Founder Corporate Officer/Principal | |
Zarodex Therapeutics Ltd.
 Zarodex Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Zarodex Therapeutics Ltd. engages in the research and experimental development on biotechnology. The company was founded on July 26, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Financial Conglomerates | Director/Board Member Founder | |
Loqus23 Therapeutics Ltd.
 Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Biotechnology | Director/Board Member Chief Executive Officer | |
Cellinta Ltd.
 Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Investment Managers | Director/Board Member Director/Board Member | |
Cybele Therapeutics Ltd.
 Cybele Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Cybele Therapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 23, 2019 and is headquartered in Reading, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Financial Conglomerates | Founder Founder | |
| Theia Therapeutics, Inc. | Director/Board Member Director/Board Member | ||
Endlyz Therapeutics, Inc.
 Endlyz Therapeutics, Inc. BiotechnologyHealth Technology Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry. | Biotechnology | Director/Board Member Director/Board Member | |
| Enara Bio Ltd. | Biotechnology | Chief Executive Officer Founder |
Statistieken
Internationaal
| Verenigde Staten | 27 |
| Verenigd Koninkrijk | 21 |
| Zwitserland | 3 |
| Australië | 2 |
| Polen | 2 |
Sectoraal
| Health Technology | 23 |
| Finance | 11 |
| Consumer Services | 9 |
| Commercial Services | 7 |
| Miscellaneous | 2 |
Operationeel
| Director/Board Member | 190 |
| Corporate Officer/Principal | 71 |
| Private Equity Investor | 52 |
| Chairman | 36 |
| Founder | 30 |
Sterkste connecties
| Insiders | |
|---|---|
| Srini Akkaraju Akkaraju | 54 |
| Kate Bingham | 31 |
| David Guyer | 27 |
| Edward Mascioli | 22 |
| Houman Ashrafian | 22 |
| W. Paul Wallace | 18 |
| Ruth McKernan | 16 |
| Allan W. May | 16 |
| Graham J. Boulnois | 14 |
| Anne Prener | 14 |
| Kevin Pojasek | 14 |
| Hamish Alan Cameron | 14 |
| Peter DiLaura | 13 |
| Aaron Sandoski | 12 |
| Simon Henry | 12 |
